Merck Jessie EnglishMerck KGaA has appointed Dr Jessie English as its new vice president of discovery, transnational innovation platform immuno-oncology.
She will take up her new role on 16 February, when she will lead the discovery team’s efforts in the exploration of disease targets and translating these into patient care.
Dr English joins Merck from the Belfer Institute for Applied Cancer Sciences at Havard Medical School’s Dana-Farber Cancer Institute where she had been head of research since March 2012.
During her two decades of work in oncology and immune-oncology research, she has also served as vice president of kinase biology at ArQule, oncology site lead for external discoveries at Merck Research Laboratories.
Prior to that she held leadership positions at both Pfizer Research and Schering-Plough Research Institute.
Source: PMLive
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
